Matches in SemOpenAlex for { <https://semopenalex.org/work/W70136901> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W70136901 endingPage "186" @default.
- W70136901 startingPage "183" @default.
- W70136901 abstract "Antibodies capable to recognize antigen expressed on cancer cells represents the ideal approach for targeted anti neoplastic therapies. The CD33 antigen is present on 90% of acute myeloid leukemia blasts and is shared on normal hemopoietic cells only on the non stem dillerentiating fraction. Gemtuzumab Ozogamicin (GO) is an engineered humanized antibody anti-CD33 conjugated with a potent intercalating agent, named calicheamicin, which is release only at intracellular level (lower pH), following a selective binding to CD33-positive cells, thus representing a promising approach for target anti-leukemia therapy. GO was approved conditionally by the Federal Drug Administration in May 2000 as a single therapy for first recurrence of Acute Myeloid Leukemia (AML) in a subset of older patients. Since 2000, treatment trials and pilot studies have revealed potential expanded applications along with potential limitations. Phase II trials have confirmed the activity and the efficacy of GO as single agent in the treatment of relapsed AML. More recently, clinical trials on induction and post-remission treatment of adult AML have shown efficacy of GO in combination chemotherapy. The strong and homogeneous CD33 expression in Acute Promyelocytic Leukemia (APL), have resulted in an effective treatment of this disease with GO used as salvage treatment, as well as innovative approach for molecular relapsed patients. However, the incidence of veno-occlusive disease, better defined as sinusoidal occlusive syndrome (SOS), must be taken into account as potential complication associated with the GO administration, especially in patients treated with ablative regimens. In conclusion, the extension of the approval in Italy to AML CD33+ in relapsed, regardless age limitation, along with the ongoing evaluation by the European EMEA, represent the basis for a large clinical application of GO in myeloid malignancies potentially extended to paediatric patients with AML and to ALL CD33+." @default.
- W70136901 created "2016-06-24" @default.
- W70136901 creator A5000262370 @default.
- W70136901 creator A5005551216 @default.
- W70136901 creator A5021283633 @default.
- W70136901 creator A5024851188 @default.
- W70136901 creator A5056860535 @default.
- W70136901 creator A5057155009 @default.
- W70136901 creator A5086238413 @default.
- W70136901 date "2005-07-01" @default.
- W70136901 modified "2023-09-23" @default.
- W70136901 title "[Therapeutic advances in neoplastic hematology: target therapy anti-CD33]" @default.
- W70136901 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16342520" @default.
- W70136901 hasPublicationYear "2005" @default.
- W70136901 type Work @default.
- W70136901 sameAs 70136901 @default.
- W70136901 citedByCount "1" @default.
- W70136901 countsByYear W701369012015 @default.
- W70136901 crossrefType "journal-article" @default.
- W70136901 hasAuthorship W70136901A5000262370 @default.
- W70136901 hasAuthorship W70136901A5005551216 @default.
- W70136901 hasAuthorship W70136901A5021283633 @default.
- W70136901 hasAuthorship W70136901A5024851188 @default.
- W70136901 hasAuthorship W70136901A5056860535 @default.
- W70136901 hasAuthorship W70136901A5057155009 @default.
- W70136901 hasAuthorship W70136901A5086238413 @default.
- W70136901 hasConcept C10205521 @default.
- W70136901 hasConcept C104317684 @default.
- W70136901 hasConcept C126322002 @default.
- W70136901 hasConcept C143998085 @default.
- W70136901 hasConcept C176290653 @default.
- W70136901 hasConcept C185592680 @default.
- W70136901 hasConcept C203014093 @default.
- W70136901 hasConcept C2776601000 @default.
- W70136901 hasConcept C2778245361 @default.
- W70136901 hasConcept C2778461978 @default.
- W70136901 hasConcept C2778623314 @default.
- W70136901 hasConcept C2778729363 @default.
- W70136901 hasConcept C2781121885 @default.
- W70136901 hasConcept C28328180 @default.
- W70136901 hasConcept C54355233 @default.
- W70136901 hasConcept C55493867 @default.
- W70136901 hasConcept C71924100 @default.
- W70136901 hasConcept C86803240 @default.
- W70136901 hasConceptScore W70136901C10205521 @default.
- W70136901 hasConceptScore W70136901C104317684 @default.
- W70136901 hasConceptScore W70136901C126322002 @default.
- W70136901 hasConceptScore W70136901C143998085 @default.
- W70136901 hasConceptScore W70136901C176290653 @default.
- W70136901 hasConceptScore W70136901C185592680 @default.
- W70136901 hasConceptScore W70136901C203014093 @default.
- W70136901 hasConceptScore W70136901C2776601000 @default.
- W70136901 hasConceptScore W70136901C2778245361 @default.
- W70136901 hasConceptScore W70136901C2778461978 @default.
- W70136901 hasConceptScore W70136901C2778623314 @default.
- W70136901 hasConceptScore W70136901C2778729363 @default.
- W70136901 hasConceptScore W70136901C2781121885 @default.
- W70136901 hasConceptScore W70136901C28328180 @default.
- W70136901 hasConceptScore W70136901C54355233 @default.
- W70136901 hasConceptScore W70136901C55493867 @default.
- W70136901 hasConceptScore W70136901C71924100 @default.
- W70136901 hasConceptScore W70136901C86803240 @default.
- W70136901 hasIssue "4" @default.
- W70136901 hasLocation W701369011 @default.
- W70136901 hasLocation W701369012 @default.
- W70136901 hasOpenAccess W70136901 @default.
- W70136901 hasPrimaryLocation W701369011 @default.
- W70136901 hasRelatedWork W1996531735 @default.
- W70136901 hasRelatedWork W1998409697 @default.
- W70136901 hasRelatedWork W2007433984 @default.
- W70136901 hasRelatedWork W2021505722 @default.
- W70136901 hasRelatedWork W2025121227 @default.
- W70136901 hasRelatedWork W2033269039 @default.
- W70136901 hasRelatedWork W2043227127 @default.
- W70136901 hasRelatedWork W2050345519 @default.
- W70136901 hasRelatedWork W2081685992 @default.
- W70136901 hasRelatedWork W2090291749 @default.
- W70136901 hasRelatedWork W2403273160 @default.
- W70136901 hasRelatedWork W2553238430 @default.
- W70136901 hasRelatedWork W2768259422 @default.
- W70136901 hasRelatedWork W2888507943 @default.
- W70136901 hasRelatedWork W2948085694 @default.
- W70136901 hasRelatedWork W3092097176 @default.
- W70136901 hasRelatedWork W3164600728 @default.
- W70136901 hasRelatedWork W3174944011 @default.
- W70136901 hasRelatedWork W2403378533 @default.
- W70136901 hasRelatedWork W2740072382 @default.
- W70136901 hasVolume "156" @default.
- W70136901 isParatext "false" @default.
- W70136901 isRetracted "false" @default.
- W70136901 magId "70136901" @default.
- W70136901 workType "article" @default.